This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Regulation (EC) No 141/2000 | |
|---|---|
| Title | Regulation (EC) No 141/2000 |
| Type | European Union regulation |
| Number | 141/2000 |
| Adopted | 2000-01-16 |
| Enacted by | European Parliament and Council of the European Union |
| Entries into force | 2000-03-04 |
| Status | amended |
Regulation (EC) No 141/2000
Regulation (EC) No 141/2000 established a framework for orphan medicinal products within the European Union, defining incentives for development and market authorisation of treatments for rare diseases. Adopted by the European Parliament and the Council of the European Union, it created procedures administered by the European Commission and the European Medicines Agency to designate and authorise medicinal products for rare conditions. The measure interacted with existing instruments such as the Orphan Drug Act in the United States and influenced subsequent legislative and regulatory practice across World Health Organization member states.
The regulation emerged amid policy debates in the late 1990s among institutions including the European Parliament, the Council of the European Union, and the European Commission about incentives for pharmaceutical innovation similar to incentives under the Orphan Drug Act overseen by the Food and Drug Administration. Debates involved stakeholders such as the European Federation of Pharmaceutical Industries and Associations, patient advocacy groups represented at venues like the European Patients' Forum, and academic contributors connected to universities such as University College London and the Karolinska Institute. The legal text drew upon principles in instruments like the Treaty on European Union and the Single European Act while aligning with regulatory practice at the European Medicines Agency and jurisprudence from the Court of Justice of the European Union.
The regulation defined orphan designation criteria for medicinal products intended to treat life-threatening or chronically debilitating rare conditions affecting populations within Member States such as France, Germany, Italy, and Spain. Its objectives included incentivising development through market exclusivity, fee reductions, and protocol assistance delivered by agencies including the European Medicines Agency and national competent authorities like the Medicines and Healthcare products Regulatory Agency in the United Kingdom and the Agence nationale de sécurité du médicament et des produits de santé in France. The text sought to balance public health priorities articulated in forums like the World Health Assembly and innovation goals echoed by organisations such as the Organisation for Economic Co-operation and Development.
Core provisions established criteria for designation—rarity thresholds, seriousness of condition, and absence of satisfactory existing treatments—administered by the European Medicines Agency's committee structures including the Committee for Orphan Medicinal Products. The regulation instituted ten-year market exclusivity comparable in effect to incentives created under the Orphan Drug Act in the United States and linked to marketing authorisation decisions by the European Commission. It provided fee waivers and reductions similar to mechanisms used by the World Intellectual Property Organization in intellectual property contexts, and set out requirements for pharmacovigilance coordinated with systems such as the EudraVigilance database. Procedural rules for designation, modification, and revocation were specified, interacting with decisions from national courts and the Court of Justice of the European Union when disputes arose.
Implementation relied on the European Medicines Agency together with national competent authorities in Member States including Sweden, Netherlands, and Poland to process applications, monitor compliance, and advise on protocols. Enforcement mechanisms included revocation grounds and withdrawal procedures tied to post-authorisation obligations and pharmacovigilance practices enforced by bodies such as the European Commission and national ministries of health like the Ministry of Health (Poland). The regulation interfaced with procedures under the Clinical Trials Directive 2001/20/EC and later the Clinical Trials Regulation (EU) No 536/2014 for trial approvals involving orphan indications, and relied on cooperation frameworks exemplified by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
The regulation stimulated orphan product development across companies ranging from multinational firms represented by the European Federation of Pharmaceutical Industries and Associations to SMEs profiled by the European Investment Bank, producing authorised therapies for conditions such as rare metabolic disorders, hemophilia, and lysosomal storage diseases. It influenced market behaviours in Member States including Belgium and Ireland and shaped patient access debates involving organisations like EURORDIS and the European Patients' Forum. Comparative analyses referenced policies including the Orphan Drug Act and national reimbursement frameworks such as those in Germany under the Gemeinsamer Bundesausschuss. Legal and economic scholarship at institutions like the London School of Economics and Harvard University examined unintended effects including pricing, market exclusivity disputes, and incentives for repurposing existing products.
Subsequent developments included procedural adaptations within the European Medicines Agency and policy refinements influenced by later instruments and case law from the Court of Justice of the European Union and legislative initiatives from the European Commission. Interactions with regulations such as the Regulation (EC) No 726/2004 and guidance from bodies like the European Directorate for the Quality of Medicines & HealthCare led to evolving designation practices, while stakeholder input from groups including EURORDIS and industry associations prompted reviews. The framework informed international dialogues with counterparts such as the Food and Drug Administration and multilaterals including the World Health Organization on orphan drug policy harmonisation and innovation incentives.
Category:European Union regulations